Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of STSA-1002 combined with STSA-1005 in healthy subjects
NCT05559125Phase 1Terminated
- Sponsor
- Staidson Biopharmaceutical
- Start
- Nov 2022
- Primary completion
- Mar 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of STSA-1002 and STSA-1005 in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Staidson Biopharmaceutical. Primary endpoint: Incidence of Adverse Events, Clinically Significant Laboratory Abnormalities, Clinically Significant Electrocardiogram, Vital Signs And Physical Examination Abnormalities at 56 days. Started Nov 2022; status: terminated.
02
Drugs
STSA-1002STSA-1005
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05559125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05559125.